GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Navidea Biopharmaceuticals Inc (OTCPK:NAVB) » Definitions » Operating Margin %

Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Operating Margin %

: 0.00% (As of Sep. 2023)
View and export this data going back to 1992. Start your Free Trial

Operating Margin % is calculated as Operating Income divided by its Revenue. Navidea Biopharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $-2.13 Mil. Navidea Biopharmaceuticals's Revenue for the three months ended in Sep. 2023 was $0.00 Mil. Therefore, Navidea Biopharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2023 was 0.00%.

Warning Sign:

Navidea Biopharmaceuticals Inc operating margin has been in a 5-year decline. The average rate of decline per year is -51.9%.

The historical rank and industry rank for Navidea Biopharmaceuticals's Operating Margin % or its related term are showing as below:

NAVB' s Operating Margin % Range Over the Past 10 Years
Min: -1017900   Med: -6199.72   Max: -440.37
Current: -1017900


NAVB's Operating Margin % is ranked worse than
99.81% of 1026 companies
in the Biotechnology industry
Industry Median: -178.545 vs NAVB: -1017900.00

Navidea Biopharmaceuticals's 5-Year Average Operating Margin % Growth Rate was -51.90% per year.

Navidea Biopharmaceuticals's Operating Income for the three months ended in Sep. 2023 was $-2.13 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Sep. 2023 was $-10.18 Mil.


Navidea Biopharmaceuticals Operating Margin % Historical Data

The historical data trend for Navidea Biopharmaceuticals's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Navidea Biopharmaceuticals Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Operating Margin %
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,358.20 -40,603.70 -9,000.84 -26,217.39 -93,673.33

Navidea Biopharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Operating Margin % Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -61,887.50 -319,800.00 - - -

Competitive Comparison

For the Biotechnology subindustry, Navidea Biopharmaceuticals's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Navidea Biopharmaceuticals Operating Margin % Distribution

For the Biotechnology industry and Healthcare sector, Navidea Biopharmaceuticals's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Navidea Biopharmaceuticals's Operating Margin % falls into.



Navidea Biopharmaceuticals Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Navidea Biopharmaceuticals's Operating Margin % for the fiscal year that ended in Dec. 2022 is calculated as

Operating Margin %=Operating Income (A: Dec. 2022 ) / Revenue (A: Dec. 2022 )
=-14.051 / 0.015
=-93,673.33 %

Navidea Biopharmaceuticals's Operating Margin % for the quarter that ended in Sep. 2023 is calculated as

Operating Margin %=Operating Income (Q: Sep. 2023 ) / Revenue (Q: Sep. 2023 )
=-2.131 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Navidea Biopharmaceuticals  (OTCPK:NAVB) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Navidea Biopharmaceuticals Operating Margin % Related Terms

Thank you for viewing the detailed overview of Navidea Biopharmaceuticals's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Navidea Biopharmaceuticals (Navidea Biopharmaceuticals) Business Description

Traded in Other Exchanges
N/A
Address
4995 Bradenton Avenue, Suite 240, Dublin, OH, USA, 43017-3552
Navidea Biopharmaceuticals Inc is a biotechnology company specializied in precision medicine. Its products, precision immunodiagnostic agents and immunotherapeutic products are designed to assist in the identification of undetected diseases and to improve targeted treatment. The company's platform, known as Manocept technology, aims to develop next-generation targeted diagnostics and therapies for cancer, autoimmune conditions, and other inflammatory diseases. One of the company's products is Lymphoseek, a radioactive diagnostic agent indicated to locate lymph nodes.
Executives
Craig Dais officer: Chief Financial Officer 4995 BRADENTON AVENUE, SUITE 240, DUBLILN OH 43017
Dana J Moss director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jill Stefanelli director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Josh M Wilson director 4795 BRADENTON AVE, STE 240, DUBLIN OH 43017
Scott John K Jr. director, 10 percent owner 30 BLUE HERON DR., GREENWOOD VILLAGE CO 80121
Agnieszka Winkler director C/O INTER-TEL, INCORPORATED, 1615 SOUTH 52ND STREET, TEMPE AZ 85281
Thomas F Farb director C/O SUMMIT PARTNERS, 222 BERKELEY ST 18TH FL, BOSTON MA 02116
Michel Mikhail officer: Chief Regulatory Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Malcolm G Witter director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Alexander L Cappello director C/O THE CHEESECAKE FACTORY INC, 26901 MALIBU HILLS ROAD, CALABASAS HILLS CA 91301
Amit Bhalla director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Joel H. Kaufman officer: Chief Business Officer 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017
Jed Latkin officer: Interim COO 152 W. 57TH STREET, 4TH FLOOR, NEW YORK NY 10019
Sarah Kathryn Rouan director 4995 BRADENTON AVENUE, SUITE 240, DUBLIN OH 43017
Claudine Bruck director 4995 BRADENTON AVE, SUITE 240, DUBLIN OH 43017-3552